Advanced Techniques in Biology & Medicine
Open Access
ISSN: 2379-1764
+44 1223 790975
ISSN: 2379-1764
+44 1223 790975
Apollo Asenath
United States Army Medical Research Directorate Kenya,
Kenya Medical Research Institute Walter Reed Project, Kisumu
Kenya
Research Article
Investigation of Markers of Artemisinin Resistance at Selected Intervals during the 72 h Period after Artemisinin based Combination Therapy Dosing in Kisumu Western Kenya
Author(s): Apollo Asenath, Lorna J Chebon, Keneth Mitei, Benjamin Opot, Dennis W Juma, Andrew Nyerere, Ben Andagalu, Hoseah M Akala and Matthew L BrownApollo Asenath, Lorna J Chebon, Keneth Mitei, Benjamin Opot, Dennis W Juma, Andrew Nyerere, Ben Andagalu, Hoseah M Akala and Matthew L Brown
Background: Microscopic parasite detection during the course of treatment or follow-up suggests that a proportion of ACT treated children in Kenya do not completely clear Plasmodium falciparum parasitemia. Plasmodium falciparum mutation in chloroquine resistance transporter gene (Pfcrt76), multidrug resistance gene1 (Pfmdr1), deubiquitinating enzyme gene (Pfcubp-1) and clathrin vesicle associated adapter 2, u subunit encoding gene (Pfap2mu) and multidrug resistant protein 1 gene (Pfmrp1) have been associated with subsequent patent recrudescence after ACT treatment. As there are no validated markers of ACT resistance in Africa to-date, surveillance of changes in these polymorphisms during the course of treatment is useful in establishing their role in ACT treatment outcome. Methods: 118 P. falciparum 2013 to 2015 samples from ACT clinical efficacy studies were genotyped for frequency o.. View More»
DOI:
10.4172/2379-1764.1000259